Tina Marriott Sells 6,000 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott sold 6,000 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $7.00, for a total transaction of $42,000.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Tina Marriott also recently made the following trade(s):

• On Thursday, August 29th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.56, for a total transaction of $45,360.00.
• On Thursday, July 25th, Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.13, for a total transaction of $48,780.00.

Recursion Pharmaceuticals Trading Down 6.4 %

Recursion Pharmaceuticals stock opened at $6.17 on Wednesday. The company has a quick ratio of 6.07, a current ratio of 6.07 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $6.95 and a two-hundred day moving average price of $8.12. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -3.86 and a beta of 0.82. Recursion Pharmaceuticals, Inc. has a 52-week low of $4.97 and a 52-week high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company’s revenue for the quarter was up 30.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.38) earnings per share. Sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on RXRX. KeyCorp dropped their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Needham & Company LLC lowered their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Finally, Jefferies Financial Group lowered their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals has an average rating of “Hold” and a consensus target price of $9.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RXRX. Benjamin F. Edwards & Company Inc. acquired a new position in Recursion Pharmaceuticals during the 1st quarter valued at about $26,000. GAMMA Investing LLC lifted its stake in shares of Recursion Pharmaceuticals by 1,588.4% in the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares during the period. Amalgamated Bank lifted its stake in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares during the period. Midwest Financial Group LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $90,000. Finally, Xponance Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $98,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.